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vastus lateralis of COPD patients with low and
normal fat free mass index and healthy controls
Roberto A Rabinovich1*, Ellen Drost1, Jonathan R Manning2, Donald R Dunbar2, MaCarmen Díaz-Ramos3,
Ramzi Lakhdar1, Ricardo Bastos3,4† and William MacNee1†Abstract
Background: Chronic Obstructive Pulmonary Disease (COPD) has significant systemic effects beyond the lungs
amongst which muscle wasting is a prominent contributor to exercise limitation and an independent predictor of
morbidity and mortality. The molecular mechanisms leading to skeletal muscle dysfunction/wasting are not fully
understood and are likely to be multi-factorial. The need to develop therapeutic strategies aimed at improving skeletal
muscle dysfunction/wasting requires a better understanding of the molecular mechanisms responsible for these
abnormalities. Microarrays are powerful tools that allow the investigation of the expression of thousands of genes,
virtually the whole genome, simultaneously. We aim at identifying genes and molecular pathways involved in skeletal
muscle wasting in COPD.
Methods: We assessed and compared the vastus lateralis transcriptome of COPD patients with low fat free mass index
(FFMI) as a surrogate of muscle mass (COPDL) (FEV1 30 ± 3.6%pred, FFMI 15 ± 0.2 Kg.m
−2) with patients with COPD and
normal FFMI (COPDN) (FEV1 44 ± 5.8%pred, FFMI 19 ± 0.5 Kg.m
−2) and a group of age and sex matched healthy
controls (C) (FEV1 95 ± 3.9%pred, FFMI 20 ± 0.8 Kg.m
−2) using Agilent Human Whole Genome 4x44K microarrays. The
altered expression of several of these genes was confirmed by real time TaqMan PCR. Protein levels of P21 were
assessed by immunoblotting.
Results: A subset of 42 genes was differentially expressed in COPDL in comparison to both COPDN and C
(PFP < 0.05; −1.5 ≥ FC ≥ 1.5). The altered expression of several of these genes was confirmed by real time TaqMan
PCR and correlated with different functional and structural muscle parameters. Five of these genes (CDKN1A,
GADD45A, PMP22, BEX2, CGREF1, CYR61), were associated with cell cycle arrest and growth regulation and had
been previously identified in studies relating muscle wasting and ageing. Protein levels of CDKN1A, a recognized
marker of premature ageing/cell cycle arrest, were also found to be increased in COPDL.
Conclusions: This study provides evidence of differentially expressed genes in peripheral muscle in COPD
patients corresponding to relevant biological processes associated with skeletal muscle wasting and provides
potential targets for future therapeutic interventions to prevent loss of muscle function and mass in COPD.
Keywords: COPD, Skeletal Muscle Dysfunction, Skeletal muscle wasting, Gene expression, Ageing* Correspondence: roberto.rabinovich@ed.ac.uk
†Equal contributors
1ELEGI Colt Laboratory, Centre for Inflammation Research, The Queen’s
Medical Research Institute, University of Edinburgh, 47 Little France Crescent,
Edinburgh, Scotland EH16 4TJ, UK
Full list of author information is available at the end of the article
© 2015 Rabinovich et al.; licensee BioMed Central. This is an Open Access article distributed under the terms of the Creative
Commons Attribution License (http://creativecommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
reproduction in any medium, provided the original work is properly credited. The Creative Commons Public Domain
Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article,
unless otherwise stated.
Rabinovich et al. Respiratory Research  (2015) 16:1 Page 2 of 15Introduction
Chronic obstructive pulmonary disease (COPD) is asso-
ciated with several extra-pulmonary effects of which
skeletal muscle wasting is one of the most extensively
studied [1,2] and results in loss of muscle strength
[1,3-6], contributes to exercise (in)tolerance [7-10] and
is a predictor of health related quality of life (HRQoL)
[11] and survival [12,13] independent of the degree of
airway obstruction [10].
Muscle wasting affects 18 to 36% of patients with COPD
[7,14] and can be present even in patients with normal
weight [7,14,15]. Indeed, muscle wasting is a better pre-
dictor of health related quality of life [11] and survival
[12,13] than body weight itself. But why does only a sub-
group of patients with COPD develop muscle wasting?;
Several patho-physiological changes, have been identified
in the skeletal muscle of COPD patients namely fibre size
reduction (atrophy) [7], fibre type redistribution [16], al-
tered bioenergetics [16], altered capillarization [17], and
altered mitochondrial function [18,19].
The molecular mechanisms leading to skeletal muscle
wasting are not fully understood and are likely to be
multi-factorial, including physical inactivity, systemic in-
flammation/oxidative stress and cell hypoxia [1] among
others.
Accumulating evidence supports the idea that COPD
is a disease of accelerated ageing [20]. It has recently
been shown that limb muscles of patients with COPD
have increased number of senescent satellite cells and an
exhausted muscle regenerative capacity, compromising
the maintenance of muscle mass in these individuals
[21] suggesting that premature cellular senescence and
subsequent exhaustion of the regenerative potential of
the muscles may relate to muscle abnormalities charac-
teristic of these patients.
Strategies to reverse skeletal muscle dysfunction/wast-
ing achieve only relatively modest improvements [22].
There is a need to develop therapeutic strategies aimed
at improving skeletal muscle dysfunction/wasting, which
requires a better understanding of the molecular mecha-
nisms responsible for these abnormalities.
Microarrays are powerful tools that allow the investi-
gation of the expression of thousands of genes, virtually
the whole genome, simultaneously. An analysis of the
genes that are being transcribed in the muscle, the tran-
scriptome, should shed light on the molecular mecha-
nisms responsible for muscle dysfunction and wasting in
COPD and can help to identify molecular targets for the
development of therapeutic strategies specifically de-
signed to improve muscle function and bulk.
In this study we assessed the transcriptome of the vastus
lateralis muscle in COPD patients with low fat free mass
index (FFMI) as a surrogate of muscle mass (COPDL) in
comparison to patients with COPD and normal FFMI(COPDN) and a group of age and sex matched healthy
controls (C).
We hypothesize that genes related to cell cycle arrest
and inhibition of cell growth will be up-regulated while
genes related to energy production and muscle devel-
opment will be down-regulated in COPDL. We expect
similarities in the transcriptome of COPDL and muscle
wasting relating to the normal ageing process. More-
over, the transcriptome analysis of this group may re-
veal important pathways leading to peripheral muscle
wasting.
This study demonstrates that vastus lateralis of pa-
tients with COPD and muscle wasting overexpress genes
related to inhibition of cell cycle and of cell growth
whilst genes related to muscle formation and growth
and energy production were down-regulated. This pat-
tern is similar to observations associated with ageing,
which suggests that premature ageing may play a role in
muscle atrophy in COPD.Methods
Study group
Nineteen stable patients with COPD, nine with low
FFMI (COPDL) and ten with normal FFMI (COPDN),
and ten age, gender and smoking status-matched healthy
subjects with normal FFMI were included in the present
study (Table 1). All patients had a diagnosis of COPD
according to the Global Initiative for Chronic Obstruct-
ive Lung Disease [23]. They were clinically stable and
free of exacerbations for 4 weeks prior to the study and
free of drugs that can potentially affect the muscle (i.e.
systemic corticosteroids, statins). The study was approved
by the Lothian Regional Ethics Committee.Measurements
Assessment
All subjects had the following baseline assessments: an-
thropometric measurements, body composition measure-
ment with bioimpedance (BIA), pulmonary function tests
(spirometry) and blood gases (Ciba Corning 800, USA),
six–minute walking distance (6MWD) [24], quadriceps
maximal voluntary contraction (QMVC) [25] (Chatillon®
K-MSC 500, Ametek, Florida), health-related quality of life
questionnaires (St. George’s Respiratory Questionnaire,
SGRQ) [26], modified Medical Research Council (mMRC)
dyspnoea scale and physical activity (PA) levels using the
Voorrips physical activity questionnaire (PAV) [27] and
the London Chest Activity of Daily Living Scale (LCADL)
[28] for patients with COPD. Number of exacerbations in
the previous year was recorded.
Low FFMI was defined as <16 kg.m−2 for male
and <15 kg.m−2 for female COPD patients [29].
Table 1 Characteristics of the study groups
COPDL COPDN Controls p-value
M/F 7/2 A 8/2 A 8/2 A ns
Age (Years) 67 ± 2.0 A 69 ± 1.5 A 68 ± 1.4 A ns
BMI (Kg.m−2) 18.8 ± 0.7 A 26 ± 0.7 B 30 ± 2.1 C <0.0001
FFMI (Kg.m−2) 15 ± 0.2 A 19 ± 0.5 B 20 ± 0.8 B <0.0001
Active/ex-smokers 1/8 A 2/8 A 2/8 A ns
Pack/year 66 ± 14 A 49 ± 6.6 AB 32 ± 5.0 B 0.037
Average cessation (years) 6.0 ± 2.5 A 8.4 ± 2.2 A 23 ± 5.5 B <0.01
Age at smoking cessation (years) 61.1 ± 8.2 A 60.5 ± 7.6 A 45.1 ± 15.5 B <0.01
mMRC 4 ± 0.4 A 3 ± 0.4 B 0.038
FEV1 (L) 0.8 ± 0.1 A 1.2 ± 0.1 A 2.8 ± 0.2 B <0.0001
FEV1 (% pred) 30 ± 3.6 A 44 ± 5.8 A 95 ± 3.9 B <0.0001
FVC (L) 2.6 ± 0.3 A 2.7 ± 0.4 A 3.9 ± 0.2 B 0.015
FVC (% pred) 76 ± 6.4 A 88 ± 9.0 AB 104 ± 3.2 B 0.01
FEV1/FVC 0.32 ± 0.1 A 0.38 ± 0.1 A 0.71 ± 0.0 B <0.0001
PaO2 (mmHg) 79 ± 7.4 A 70 ± 3.1 A 73 ± 1.8 A ns
PaCO2 (mmHg) 43 ± 2.0 A 41 ± 1.1 A 42 ± 0.6 A ns
Physical activity (V) 1.2 ± 0.3 A 7 ± 1.9 B 11 ± 1.5 B <0.0001
Physical activity (L) 43 ± 3.6 A 30 ± 5.0 A ns
QMVC (N) 213 ± 19.4 A 323 ± 25.6 B 366 ± 26.8 B 0.002
6MWD (m) 306 ± 55 A 411 ± 50.1 AB 524 ± 37.9 B 0.01
BODE 6.5 ± 1.3 A 4 ± 0.9 A ns
SGRQ Symptoms 76 ± 4.8 A 60 ± 4.2 B 0.01
SGRQ Activity 86 ± 4.7 A 52 ± 9.2 B 0.003
SGRQ Impact 57 ± 6.6 A 33 ± 7.7 B 0.01
SGRQ Total 69 ± 5.4 A 43 ± 6.8 B 0.005
Type I Fibre (%) 25.1 ± 4.6 A 24.4 ± 3.3 A 38.7 ± 3.9 B 0.04
Type II area (μ2) 2033 ± 166 A 2978 ± 277 B 2564 ± 277 AB 0.03
Definition of abbreviations: COPDN = COPD patients with normal FFMI; COPDL = patients with COPD with low FFMI; BMI = Body mass index; FFMI = fat free mass
index; MRC =medical research council dyspnoea score; FEV1 = forced expiratory volume in the first second; FVC = forced vital capacity; PaO2 = arterial oxygen
partial pressure; PaCO2 = arterial carbon dioxide partial pressure; Physical Activity (V) = Voorrips Questionnaire; Physical activity (L) = London Chest Activity of Daily
Living Scale; QMVC = quadriceps maximal voluntary contraction; 6MWD = six minute walking distance; SGRQ = St. George’s Respiratory Questionnaire; ns = not
significant; NA = not applicable. Comparisons among groups were done using ANOVA and Student-Newman-Keuls as a post-hoc test. Differences among the three
different groups were stated using letters A, B and C where sharing a letter implies no differences between these groups and having a different letter implies a
statistical difference in the post-hoc test.
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An open muscle biopsy of the “vastus lateralis” was
obtained and ~0.1 g was included in RNA stabilization
reagent (RNAlater®, Ambion, Inc., USA) and stored
at −20°C for RNA extraction. Total RNA was extracted
and purified by homogenisation (TissueLyser, Qiagen Ltd.
West Sussex, UK) of tissue employing the TRIzol® Plus
RNA Purification Kit (Invitrogen Life Technologies,
Carlsbad, CA).
Fibre type typification
Paraffin sections (5um) were de-waxed and re-hydrated
through graded ethanol using standard procedures. Sec-
tions were placed in 250 ml of Novocastra pH8 retrievalbuffer and subjected to antigen retrieval in a de-cloaking
chamber (Biocare Medical, USA) using a protocol de-
scribed elsewhere [30].Microarray hybridization and data analysis
Five hundred nanograms of total RNA from each sample
was converted into labelled cRNA with nucleotides
coupled to a fluorescent dye (Cy3) using the Quick Amp
Kit (Agilent Technologies, Palo Alto, CA). Cy3-labeled
cRNA (1.65 μg) was hybridized to Agilent Human
Whole Genome 4×44K Microarrays (Agilent Technolo-
gies, Santa Clara, CA). The hybridized array was then
washed and scanned and the data were extracted from
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(Agilent Technologies).
Pre-processing (background correction, normalization,
filtering and summarization) subsequent data processing
and analysis was performed using the Agi4x44 Pre-
process module from Bioconductor [31,32].
The Rank Product [33,34] was employed for the micro-
array data analysis. RP is a non-parametric algorithm that
detects probes/genes consistently highly ranked by fold-
change between samples from different groups and em-
ploys a ‘percent false positives’ (PFP) measure, also known
as false discovery rate (FDR), to select the most significant
differential expressions. A percentage of false positive
(PFP) below 0.05 was considered statistically significant.
The gene functional enrichment analysis was per-
formed using DAVID Bioinformatics Resources (http://
david.abcc.ncifcrf.gov/). Specifically, the Functional Anno-
tation Chart tool was used to enrich the over-represented
Gene Ontology (GO) terms among the differentially
expressed gene list. A list of all detectable transcripts was
used as the background for the GO analysis [35]. The GO
terms after correction for FDR at p < 0.05 (Benjamini
Hochberg) were selected for further analysis and
interpretation.
Ingenuity Pathway Analysis (IPA, Ingenuity Systems,
Redwood, CA) was used to further investigate the Gene-
spring expression clusters [36].
qPCR validation
Based on microarray-derived fold-change (>2) or statis-
tical significance for differential expression and/or the
biological relevance for the different comparisons, 11
genes were selected for TaqMan qPCR validation (Ap-
plied Biosystems).
Western blot analysis
P21, the protein encoded by the CDKN1A gene was deter-
mined using immunoblotting. 20 μg of protein was
resolved by sodium-dodecyl sulfate-polyacrylamide gel
electrophoresis on 10% polyacrylamide gels. Proteins were
transferred to Immobilon-P PVDF membranes (Millipore,
Billerica, MA), blocked with 5% dry milk (Bio-Rad,
München, Germany) in TBS (Sigma) overnight at 4°C
and probed with primary antibodies primary antibody
against p21 (ab 7960) (Abcam, Bristol, UK) during 1 h
at room temperature. Proteins were then visualized
using the ECL Detection System (Pierce, Rockford, IL)
as per the manufacturer’s instructions.
Statistical analysis
Anthropometric, physiological data and immunobloting
results for p21 are expressed as mean ± SEM. These data
were analysed using ANOVA with Student-Newman-
Keuls as a post-hoc test. Correlation analysis betweenvariables was conducted using Pearson’s correlation
index for continuous variables and Spearman’s correl-
ation index for categorical variables. For the qPCR valid-
ation analysis differential expression analysis on
individual sample values of ΔCT using Kruskal Wallis
with a Nemenyi-Damico-Wolfe-Dunn post-hoc test was
performed.
The statistics were conducted using the statistical pack-
age SAS version 9.3 (SAS Institute Inc, Cary, NC, USA). A
p value <0.05 was taken as statistically significant.
Full details of the methods can be found in the
Additional file 1.
Results
Anthropometric characteristics and pulmonary function
data of study subjects are depicted in Table 1. Both groups
of COPD patients showed airflow limitation compared to
healthy controls (C) who all had normal spirometry, but
there were no differences in spirometry between COPDN
and COPDL (Table 1 and Additional file 2: Figure S1). Pa-
tients were matched by smoking status (two COPDN, one
COPDL patient and two healthy controls were active
smokers at the time of inclusion, p = ns). All subjects,
including healthy controls, were exposed (current or ex-
smokers) to cigarette smoking (no never-smokers were
included in the study). Moreover, no differences in the
number of years of smoking cessation was seen between
COPDL (6.0 ± 2.5 years) and COPDN (8.4 ± 2.2 years) nor
in the age of the patients when they stopped smoking
(61.1 ± 8.2 years old) COPDL and (60.5 ± 7.6 years)
COPDN. Both COPD groups showed less years of smok-
ing cessation than controls (23.2 ± 5.5 years) (ANOVA
P < 0.01).
Compared to C, COPDN had lower BMI and physical
activity and COPDL had very different anthropometric
characteristics.
Compared to COPDN, COPDL had significantly lower
BMI, FFM and FFMI, poorer HRQoL with higher values
in all of the domains of the St. George’s respiratory ques-
tionnaire, higher mMRC score and worse muscle func-
tion as assessed by QMVC. They also had lower levels of
physical activity measured by the Voorrips questionnaire
(PAV) but no difference were seen in activities of daily
living (ADL) assessed with the LCADL (PAL), specifically
designed to assess ADL in patients with COPD
(Table 1).
Both COPD groups showed a redistribution of muscle
fibre type with a higher proportion of type II fibres and
a lower proportion type I in comparison to healthy con-
trols. Type II fibre area was significantly reduced in
COPDL in comparison with COPDN (Table 1).
In the whole COPD population FFMI correlated
with FEV1 (r = 0.51, p < 0.05), mMRC dyspnoea score
(rho = −0.48, p < 0.05), QMVC (r = 0.76, p < 0.001), and
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muscle function (QMVC) correlated with FFMI (r = 0.76,
p < 0.0001), exacerbation rate (rho = −0.57, p < 0.05),
6MWD (r = 0.62, p < 0.01), physical activity (PAV) (r = 0.53,
p < 0.05) and BODE index (rho =−0.66, p < 0.05).
Global assessment of gene expression
Hierarchical and k-means clustering were undertaken
with normalized data. No pattern emerged from this
analysis. We therefore performed three pair-wise class
comparisons: COPDL vs. COPDN, COPDL vs. C and
COPDN vs. C, employing Rank Products (RP) to detect
differentially expressed genes (DEGs). First, a list of up-
or down-regulated genes for each comparison was se-
lected based on a PFP <0.05 (Table 2) (no FC criterion
was applied). Comparisons of both groups COPD pa-
tients with C showed the most differentially expressed
genes and the comparison between the COPD groups
the least.
In order to select the most relevant DEGs related to
muscle wasting in COPD, we selected a list of DEGs be-
tween COPDL and COPDN. Furthermore, among this
list, we selected those genes that were also differentially
expressed between COPDL and C (Figure 1). This list of
1110 DEGs (1763 probes) (454 DEGs up-regulated and
656 DEGs down-regulated) was used to conduct a func-
tional enrichment analysis. Table 3 displays the most
characteristic GO biological processes (with 8 or more
genes representing each class/category/pathway) that
were enriched in this list. Significant GO classes from
the list of up-regulated DEG correspond to functional
terms related to protein synthesis, muscle organ devel-
opment and striated muscle contraction while functional
terms related to glucose metabolism, energy production,
striated muscle development and striated muscle con-
traction were identified from the list of down-regulated
genes.
Since some of these DEGs displayed marginal changes
in gene expression, we applied a more restrictive criter-
ion, namely a fold change cutoff of 1.5 (1.5 ≥ FC ≥ 1.5) in
order to select more robust genes. Figure 2 shows the
list of DEGs generated between COPDL and both other
groups of subjects with normal muscle mass using this
criterion. When the combined criteria of both statisticalTable 2 DEGs between COPDL, COPDN and C
COPDL vs COPDN COPDL vs C COPDN vs C
Up regulated Probes 954 1352 1050
Genes 531 830 724
Down
regulated
Probes 1054 1631 1201
Genes 748 1152 799
DEGs between COPDL vs. COPDN, COPDL vs. C and COPDN vs C. Number of up
and down regulated probes and genes with a PFP < 0.05 in all three comparisons.significance and fold change were applied the numbers
of DEGs were notably reduced. Eighty three probes,
representing 64 DEGs, were identified between COPDL
and COPDN. Fifty six of these probes, representing
42 DEGs, were also differentially expressed between
COPDL and C (Table 4 and 5). These 42 DEGs were se-
lected for further analysis. Although this shorter list of
genes was not suitable for a functional enrichment ana-
lysis, the biological significance of these genes was
related with the significant functional categories identi-
fied in the list of 1110 DEGs originally obtained with a
PFP < 0.05. Among the up-regulated genes (Table 4)
from this list of 42 DEGs, we have identified genes related
to cell cycle inhibition and inhibition of cell growth
(CDKN1A, GADD45A, PMP22, BEX2, CGREF1, CYR61),
inhibition of sarcomeric organization (HDGF), stress in-
ducible factor (ATF3), inhibition of glucose metabolism
(PDK4), lipid metabolism (LPL), aminoacid transportation
(SLC22A3, SLC38A1), muscle repair (ABRA) and myo-
genesis (NNMT, ANKRD1). Among the down-regulated
genes (Table 5) we have identified genes related to fatty
acid synthesis (MCAT), muscle formation (CHRDL2,
IRX4, PMEPA1), glucose endocytosis (RAB10) and gluco-
neogenesis (GPT).
Relationship with muscle structure and function
In order to identify bona fide muscle wasting associated
genes we selected, from this subset of 42 DEGs, those that
correlated with FFMI in the whole population including
the healthy control. Ten out of twenty six of the up-
regulated DEGs were negatively correlated with FFMI
while nine out of the sixteen down-regulated DEGs were
positively correlated with FFMI (Table 6).
Since COPDL were characterized by type II fibre atro-
phy in comparison with COPDN, we explored the correla-
tions between these DEGs and type II fibre area. Three
of the up-regulated DEGs (PMP22, CGREF1 and LPL)
were negatively correlated with type II fibre area while
four of the down-regulated DEGs (SAA1, CHRLD2,
and FARP1) were positively correlated with type II fibre
area (Additional file 3: Table S1). In turn, several of
the up-regulated (ANKRD1, CDKN1A, GADD45A, ATF3,
RAB15, ABRA and SLC22A3) and down-regulated
(EVX1, PMEPA1, GPT, RAB10, SPSB1) DEGs in
COPDL correlate with the proportion of Type II fibres
(Additional file 4: Table S2). Moreover several up-
regulated (negatively) and down-regulated (positively)
DEGs correlated with QMVC, a measurement of
muscle function (Additional file 5: Table S3).
qPCR validation
Eleven genes (CDKN1A, CEBPA, CYR61, EFCAB7, EGR1,
HMOX1, PDE11A, SAA1, SLC22A3, SLC38A1 and
SLC43A2) were selected for qPCR validation of the
142
COPDL vsCOPDN COPDLvs C
245
1110
843
1763
1220
Figure 1 Venn diagram showing the numbers of genes (black) and probes (white) differentially expressed between COPDL and both
other groups without muscle wasting (COPDN and C) (PFP < 0.05).
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derived fold-change (>2) or statistical significance for dif-
ferential expression and/or the biological relevance for the
different comparisons (COPDN vs COPDL, COPDN vs C
and COPDL vs C) (Figure 3A and Additional file 6:
Figure S2). As shown in Table 7, the altered expression
of all these genes was confirmed by real time TaqMan
PCR.
Figure 3A shows qPCR data for CDKN1A, one of the
six genes representing the group of genes related to cell
cycle inhibition and inhibition of cell growth from the list
of 42 DEGs identified between COPDL and both other
groups of subjects with normal muscle mass. CDKN1A
mRNA expression was increased in COPDL compared
to both COPDN and C (p < 0.005) (Graphics for the
remaining eight genes are depicted in the Additional
file 6: Figure S2). The expression of several of theseTable 3 GO Terms associated with relevant genes related to m
Source GO terms
Up-regulated genes
Traslational initiation
Traslational elongation
Ribosomal biogenesis
rRNA processing
Muscle organ development
Striated muscle contraction
Down-regulated genes
Glucose metabolic process
Energy derivation by oxidation of organic com
Electron transport chain
ATP synthesis coupled electron transport
Striated muscle tissue development
Muscle contraction
GO Terms associated with DEGs between COPDL vs. COPDN and COPDL vs. C.
Functional enrichment analysis of 454 up-regulated and 656 down-regulated DEGs be
term, the fold enrichment, number of genes involved in the term and the FDR (False dgenes assessed by qPCR correlated with parameters
of muscle structure and function. CDKN1A and
ANKRD1 correlated with percentage of Type II fibres
(Figure 4), CEBPA, CYR61, EFCAB7, SLC22A3 and
SLC38A1 correlated negatively with FFMI (Figure 5). In
turn, CEBPA correlated positively (rho = 0.45, p < 0.05)
while SLC43A2 correlated negatively (rho = −0.65, p <
0.0005) with the proportion of Type II fibres. Moreover,
CDKN1A, CYR61, CEBPA, EFCAB7, SLC22A3 corre-
lated negatively with QMVC, a measurement of muscle
function (Additional file 7: Figure S3).
Immunobloting
As CDKN1A was differentially expressed between COPDL
and COPDN but also between COPDL and C, with a fold
change over 1.5, and it also correlated with several
measurements of skeletal muscle structure and functionuscle wasting
Fold enrichment No of gene in the term FDR
7.9 11 0.001
14.7 49 6.05E-42
4.2 17 0.004
4.9 15 0.002
3.2 20 1.62E-05
6.5 10 1.55E-05
3.3 21 0.008
pounds 5.8 37 4.86E-15
6.2 31 5.77E-13
9.3 22 1.91E-12
3.4 18 0.02
4.7 31 1.94E-09
tween COPDL vs. COPDN and COPDL vs. C (FDR < 0.05) with the corresponding GO
iscovery Rate).
4222 121
COPD
L
vs COPD
N
C vs COPD
L
56
27 165
Figure 2 Venn diagram showing the numbers of genes (black) and probes (white) differentially expressed between COPDL and both
other groups without muscle wasting (COPDN and C) (PFP < 0.05; −1.5 ≥ FC ≥ 1.5).
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characterised by muscle wasting, we chose to explore the
protein levels of p21 in our samples by immunoblotting.
This showed that p21 is over expressed in COPDL in com-
parison to both COPDN and C (Figure 3B). However, only
the comparison between COPDL and COPDN was statisti-
cally significant.
Discussion
This study shows relevant changes in gene expression in
the vastus lateralis of COPD patients with skeletal
muscle wasting. We identified several up-regulated
genes associated with cell cycle arrest and growth regu-
lation, and down-regulated genes associated with muscle
formation and glucose metabolism in patients with low
FFMI. These DEGs correlated with several parameters of
muscle structure and function. The altered expression of
11 genes was confirmed by qPCR and the increased level
in COPDL of P21, the protein encoded by CDKN1A,
was also corroborated by immunoblotting.
Our initial approach revealed extensive changes in gene
expression that allowed us to identify several biologically
relevant GO terms related to protein synthesis, muscle
contraction and muscle organ development (from the up-
regulated list of genes in COPDL) and oxidative energy
production, glucose metabolism and striated muscle con-
traction and myogenesis (from the down-regulated list of
genes in COPDL). The concomitant activation and de-
regulation of different genes involved in myogenesis reveal
the complex nature of the muscle wasting process in this
population of patients. This, together with the activation
of genes related to protein synthesis, show a potentially
adaptive, yet clearly ineffective, response at maintaining
muscle mass [37].
Using a more restrictive approach we were able to
discard genes with potential marginal changes and
identify a subset of more substantial DEGs. This group ofDEGs fulfil several criteria: a) they were differentially
expressed between COPDL and COPDN, b) showed a fold
change ≥1.5 or ≤1.5 between COPDL and COPDN, c) were
also differentially expressed between COPDL and C, b)
showed a fold change ≥1.5 or ≤1.5 between COPDL
and C. These criteria markedly reduced the list of
DEGs but reinforced the relevance of these genes for
the process of muscle wasting. This approach identified
up-regulated DEGs related to the inhibition of cell growth
and cell cycle and down-regulated genes related to myo-
genesis and glucose metabolism in COPDL. Several of
these DEGs correlate with FFMI, parameters of muscle
structure and function such as type II fibre size (the fibres
showing atrophy in COPDL), the proportion of type II fi-
bres and QMVC, indicating a potential role of these genes
in the muscle wasting process.
Among these DEGs, GADD45A is induced by DNA
damage [38] and stress (such as fasting or immobilization)
[39,40]. GADD45A represses genes involved in anabolic
signalling and energy production and induces pro-atrophy
genes [39,40]. Interestingly, genes related to energy
production by oxidation and glucose metabolic pro-
cesses were down-regulated in our population of COPDL.
GADD45A [41] and CDKN1A [42-44] have previously
been identified in several conditions associated with
muscle atrophy. Moreover, myostatin suppresses muscle
cell growth via the transcriptional regulation of CDKN1A
[45]. p21, the protein encoded by this gene, can inhibit
apoptosis (when present in the cytosol by arresting the cell
cycle allowing for DNA repair) or promote apoptosis (in
the nucleus and interacting with other proteins) [38,46,47].
The interaction between p21 and growth arrest and DNA
damage-inducible genes such as GADD45A results in
apoptosis [38]. Furthermore, CDKN1A and GADD45A are
also related to other muscular disorders such as amyo-
trophic lateral sclerosis [43]. ATF3, another of the DEGs
up-regulated in COPDL, together with GADD45A and
Table 4 Up-regulated DEGs between COPDL vs. COPDN
and COPDL vs. C with a FC over 1.5
PROBE Gene symbol COPDL vs. COPDN COPDL vs. C
PFP FC PFP FC
A_32_P200144 IGHG1 0.044 5.3 0.0177 9.4
A_23_P43979 IGLL5 0.0435 5.1 0.0133 7.9
A_24_P104980 IGLL5 0.0252 4.3 0.0098 6.5
A_23_P398566 0.0133 2.9 0.0491 1.7
A_23_P46429 CYR61 0 2.8 0 2.9
A_24_P370946 CYR61 0.0009 2.7 0.0013 2.7
A_23_P46426 CYR61 0.0008 2.5 0.0005 2.6
A_23_P161218 ANKRD1 0.0074 2.5 0.0067 1.9
A_24_P376707 HDGF 0.0402 2.5 0.0169 2.6
A_23_P19733 SLC22A3 0.0004 2.4 0 4.6
A_23_P34915 ATF3 0.0062 2.1 0.0011 3.4
A_32_P60459 OTUD1 0 2.0 0 2.6
A_32_P219135 0.012 2.0 0.0042 2.4
A_23_P166248 RCAN1 0.0162 1.9 0.0417 1.6
A_23_P22735 BEX2 0.0085 1.9 0.0003 3.2
A_23_P127584 NNMT 0 1.9 0 3.0
A_23_P100711 PMP22 0 1.8 0 2.2
A_23_P49338 TNFRSF12A 0.0022 1.8 0.0019 1.8
A_23_P363399 SLC38A1 0.0257 1.8 0.0027 3.0
A_23_P146233 LPL 0.0003 1.8 0.0022 1.5
A_24_P243749 PDK4 0 1.7 0 1.6
A_23_P403445 CGREF1 0.0353 1.7 0.0446 1.6
A_24_P193295 RAB15 0.0004 1.7 0.0002 1.9
A_23_P208540 LOC644482 0.0095 1.7 0.0026 1.8
A_24_P261734 SLC38A1 0.0148 1.7 0.0012 2.9
A_23_P408095 DSTN 0.0091 1.6 0.033 1.6
A_23_P418031 0.0133 1.6 0.0169 1.7
A_23_P314024 HLA-F 0.0075 1.6 0.0026 1.8
A_23_P166109 FLRT3 0.0419 1.6 0.0145 1.8
A_23_P59210 CDKN1A 0.0074 1.5 0.0014 2.2
A_23_P23221 GADD45A 0.0055 1.5 0.0016 1.7
A_32_P234459 HLA-H 0.0206 1.5 0.0103 1.7
A_23_P350295 0.0009 1.5 0.0003 1.7
A_24_P50489 0.0024 1.5 0.0008 1.5
A_23_P125109 0.0036 1.5 0.0002 1.7
A_23_P313482 ABRA 0.0003 1.5 0.0002 1.5
All probes are differentially expressed with a PFP (percentage of false
positive) <0.05 and a FC (fold change); −1.5 ≥ FC ≥ 1.5.
Table 5 Down-regulated DEGs between COPDL vs. COPDN
and COPDL vs. C with a FC over 1.5
PROBE Gene symbol COPDL vs. COPDN COPDL vs. C
PFP FC PFP FC
A_24_P401294 FLJ35934 0 −1.5 0 −1.5
A_24_P96961 SPSB1 0.0076 −1.5 0.0004 −2.2
A_24_P576591 0.0206 −1.5 0.0096 −1.5
A_24_P319675 RAB10 0.0105 −1.5 0 −2.8
A_23_P57089 PMEPA1 0.0056 −1.5 0.0005 −1.8
A_23_P146339 GPT 0.0013 −1.6 0.0007 −1.6
A_23_P308763 FARP1 0.0047 −1.6 0.0018 −1.7
A_24_P419028 MOP-1 0.0124 −1.6 0.0013 −1.8
A_23_P37856 HBA2 0.0003 −1.6 0 −2.4
A_23_P205355 SERPINA5 0.0377 −1.7 0.0031 −2.2
A_24_P413126 PMEPA1 0.0064 −1.7 0.0006 −1.9
A_24_P368943 EVX1 0.0006 −1.7 0.0002 −1.7
A_23_P26457 HBA2 0.0005 −1.8 0 −2.5
A_32_P163891 0.0344 −1.8 0.0104 −2.4
A_24_P75190 HBD 0.0003 −1.9 0 −3.1
A_24_P20795 IRX4 0.0055 −1.9 0.005 −1.9
A_23_P13548 CHRDL2 0.0139 −2.0 0.0452 −1.6
A_24_P412734 PRSS36 0.0474 −2.3 0.0039 −1.9
A_24_P237328 MCAT 0.0483 −2.4 0.0123 −1.8
A_24_P335092 SAA1 0.0207 −2.6 0.0003 3.8
All probes are differentially expressed with a PFP (percentage of false
positive) < 0.05 and a FC (fold change); −1.5 ≥ FC ≥ 1.5.
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sponse to DNA damage [48]. ATF3 is induced by stress
and is related to cardiac contractility abnormalities [49] and
muscular disorders such as amyotrophic lateral sclerosis
[43]. ATF3 gene expression correlated negatively with FFMIand QMVC in our population. Another gene up-regulated
in COPDL, ANKRD1, has been associated with up-
regulation of p21, one of its downstream targets [50].
ANKRD1 is expressed in the muscle and migrates to the
nucleus when the muscle is under stress. It has been shown
to be up-regulated during muscle atrophy [51]. Evidence
suggests that ANKRD1 per se cannot initiate atrophy.
However, the observation that p21 is increased whenever
ANDRD1 is increased in different models of muscle atro-
phy highlights the importance of this interaction in the
muscle wasting process [50]. Moreover, a switch towards
fast-twitch fibres has been reported in models of atrophy in
association with up-regulation of ANKRD1 [50]. It is of
note that ANKRD1 expression was negatively correlated
with FFMI and QMVC and positively correlated with the
proportion of Type II fibres in our COPDL, as were
CDKN1A, GADD45A1 and ATF3. GADD45A1 also corre-
lated negatively with muscle function measured as QMVC.
CDKN1A has also been shown to interact with CEBPA
[46] leading to cell arrest [38], and was up-regulated in
COPDL and confirmed by qPCR. In fact, CEBPA inhibits
cell proliferation by stabilising p21 [52] and protecting
against its degradation [53]. CEBPA and CDKN1A gene
expression assessed by qPCR correlated negatively with
Table 6 DEGs between COPDL and both COPDN and C that
that varied with percentage of FFMI
Source Probe Gene symbol rho p
Up-regulated genes
A_23_P22735 BEX2 −0.55 0.0019
A_23_P100711 PMP22 −0.48 0.0085
A_23_P166109 FLRT3 −0.4 0.0327
A_24_P193295 RAB15 −0.44 0.0167
A_23_P46426 CYR61 −0.38 0.0391
A_24_P370946 CYR61 −0.39 0.0358
A_23_P46429 CYR61 −0.39 0.0337
A_24_P261734 SLC38A1 −0.47 0.0098
A_23_P363399 SLC38A1 −0.47 0.01
A_23_P19733 SLC22A3 −0.55 0.002
A_23_P49338 TNFRSF12A −0.36 0.05
A_32_P219135 −0.45 0.015
A_23_P34915 ATF3 −0.36 0.055
A_23_P161218 ANKRD1 −0.47 0.0099
Down-regulated genes
A_23_P13548 CHRDL2 0.44 0.017
A_24_P20795 IRX4 0.36 0.056
A_24_P368943 EVX1 0.36 0.057
A_24_P413126 PMEPA1 0.52 0.0034
A_23_P57089 PMEPA1 0.57 0.0012
A_23_P205355 SERPINA5 0.5 0.0054
A_24_P419028 MOP-1 0.37 0.045
A_23_P146339 GPT 0.36 0.054
A_24_P319675 RAB10 0.64 0.0002
A_24_P401294 FLJ35934 0.44 0.0157
Significant associations between up-regulated and down-regulated DEGs and
FFMI. rho: spearman correlation index.
Figure 3 qPCR (panel A) and Immunoblotting (panel B) results
for CDKN1A and p21 respectively showing differential
expression in COPDL) (*p < 0.05).
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up-regulation of these genes in COPDL together with the
strong association with FFMI, and parameters of skeletal
muscle structure and function suggest that cell cycle arrest
followed by apoptosis play a role in the process of muscle
wasting in this population in response to stress. The pres-
ence of muscle cell apoptosis in peripheral muscle of pa-
tients with COPD is still controversial. Some groups have
reported increased cell apoptosis, assessed as DNA frag-
mentation [54,55], whereas others failed to report apop-
tosis, assessed as active caspase-3 [56]. It is interesting
that, as mentioned previously, p21 has a dual function and
can promote or inhibit apoptosis [38,46,47]. Apoptosis
induced by p21 is distinct from that induced by other pro-
apoptotic agents and does not involve activation of cas-
pases [38]. In fact, while the carboxyl terminus interacts
with molecules such as GADD45A or CEBPA, the N-
terminus can interact with procaspase-3 to block activa-
tion of caspase-3 [57]. Hence, apoptosis induced by p21 is
not affected by caspase inhibitors [38]. This may explainthe controversy in the literature regarding muscle cell
apoptosis in peripheral muscle of patients with COPD.
Other genes known to be overexpressed under stress
situations and inflammation were also up-regulated in
COPDL, such as CYR61 whose expression increases with
exercise in humans [58-60]. CYR61 is required for the
migration of myoblasts during the regeneration process
[61] and mediates angiogenesis [60,62]. On the other
hand, CY61 is increased in the muscle in models of mal-
nutrition [63] and muscle denervation [64] and pro-
motes cell migration and immobilise inflammatory cells
in the site of inflammation and tissue repair [65]. More-
over, CYR61 gene expression assessed by both, micro-
array and qPCR, correlated negatively with FFM and
QMVC in our population. In line with these findings,
oxidative stress has been consistently shown in limb
muscle of patients with COPD [66], particularly in
patients with muscle wasting [67]. While local muscle
oxidative stress is induced by exercise [67], the exercise-
induced increase in antioxidant enzymes is attenuated or
inhibited in the muscle of underweight patients with
COPD [68,69]. HMOX1, a gene involved in the response
to oxidants known to protect against cytotoxicity of oxi-
dative stress and nitric oxide metabolism, was down-
regulated in our population of COPD [70]. In turn,
although not consistently shown, some authors have
Figure 4 Correlations between percentage of Type II fibres
(x axis) and qPCR gene expression (corrected by GAPDH
housekeeping gene (ΔΔCt) CDKN1A panel A; ANKRD1 panel B)
in COPDL (o), COPDN (●) and C (■) (y axis). Solid line represents
regression line and dashed lines 95% CI.
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muscle of patients with COPD [71-73]. Regardless of
the presence of inflammatory markers, activation of nu-
clear factor kB (NFkB) in peripheral muscle of patients
with COPD suggests an increased inflammatory state
[66,74-76]. TNFRS12A, a direct kB target, also known asTable 7 qPCR Validation of microarray experiment
Gene symbol Microarray selection criteria qPCR result
CDKN1A PFP <0.005, FC 2.19 COPDL vs C p < 0.005
CEBPA PFP <0.005, FC 2.08 COPDL vs C p < 0.005
CYR61 PFP <0.005, FC 2.6 COPDL vs C p < 0.005
EFCAB7 PFP <0.005, FC 2.63 COPDL vs C p < 0.005
EGR1 PFP <0.005, FC −2.11 COPDN vs C p < 0.05
HMOX1 PFP <0.005, FC −2.31 COPDL vs C p = 0.06
PFP <0.005, FC −2.26 COPDN vs C p < 0.05
PDE11 PFP <0.005, FC −2.28 COPDL vs C p < 0.05
SAA1 PFP <0.005, FC 3.8 COPDL vs C p < 0.005
PFP <0.005, FC 10.1 COPDN vs C ns
SLC22A3 PFP <0.005, FC 2.46 COPDL vs COPDN ns
PFP <0.005, FC 4.62 COPDL vs C p < 0.05
SLC38A1 PFP <0.005, FC 3.02 COPDL vs C p < 0.005
SLC43A2 PFP <0.005, FC −2.1 COPDL vs C p < 0.005
Comparative results of eleven selected genes for validation between
microarrays and qPCR.TWEAK, is known to induce muscle wasting in whole
muscle [77] and required for denervation atrophy [78], an
effect mediated by NFkB [51,77]. TNFRS12A was up-
regulated in COPDL and negatively correlated with FFMI
and QMVC in our population.
The maintenance of skeletal muscle bulk results from
the interaction of mechanisms leading muscle wasting
(i.e. cell death, protein degradation) and muscle regener-
ation and protein synthesis. Several genes related to
muscle development and regeneration (PMEPA1, IRX4,
CHRDL2) were down-regulated in the COPDL [79,80].
Some groups have investigated key markers of muscle
regeneration in peripheral muscle of patients with
COPD, although the evidence is unclear due to the lack
of longitudinal data. Plant et al. (80) showed no differ-
ences in skeletal muscle expression of muscle-specific
transcription factors associated with muscle differenti-
ation Myf5, MyoD or myogenin. Crul et al. [81] showed
no differences in MyoD in stable COPD patients. How-
ever, patients undergoing an exacerbation presented with
reduced levels of MyoD compared to healthy controls
(78). Thériault et al. have recently shown that besides
greater number of attempts to regenerate the muscle,
there was a profound reduction in the differentiation po-
tential in COPD patients peripheral muscle [82]. Vogiatzis
et al. (123) showed that exercise training increased the ex-
pression of MyoD in peripheral muscle of patents with
COPD. Lewis et al. (124) showed an increment in IGF-I
protein (an activator of cell growth and proliferation and
an inhibitor of apoptosis) with exercise training and a
combination of exercise training and testosterone to-
gether with an increment in myogenin mRNA expression.
The role of impaired muscle regeneration, potentially in
some circumstances (e.g. exacerbations), remains to be
elucidated.
Comparison with other studies
We have identified other studies assessing peripheral
muscle gene expression in COPD and other medical
conditions associated with muscle cachexia, namely in-
tensive care (ICU) patients [83] and cancer [84], as well
as ageing-associated muscle wasting [85,86] and studies
exploring the effect of exercise training on gene expres-
sion in muscle of healthy subjects [87].
Despite differences in the populations and the method-
ology, which oblige to be cautious when comparing stud-
ies, we found interesting similarities with our results.
Two studies have explored gene expression in peripheral
muscle of patients with COPD [88,89]. Debigaré [88] et al.
compared vastus lateralis gene expression profiles from
COPD patients with muscle atrophy and healthy controls.
They have also found down regulation of genes involved
in energy production and up-regulated genes related to
cell cycle arrest including CDKN1A in the population of
Figure 5 Correlations between FFMI (x axis) and qPCR gene expression corrected by GAPDH housekeeping gene (ΔΔCt) in COPDL (o),
COPDN (●) and C (■) (y axis). Solid line represents regression line and dashed lines 95% CI.
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while several relevant genes from our study were also
identified by other studies involving stable COPD patients
[88] this was not the case in studies involving hospitalized
patients [89], however, as in our study, pro-inflammatory
genes, such as SAA, were identified in the exacerbated
patients.
In addition, our results have similarities with other
inflammatory medical conditions associated with muscle
wasting, such as sepsis [83], and also in association with
ageing [85,86]. Similarly to our population, genes encod-
ing proteins involved in muscle metabolism are down-
regulated in association with ageing. Moreover, genes
involved in cell cycle regulation and apoptosis are also
affected by age. CDKN1A was up-regulated in the two
mentioned studies in association with ageing. The
similarities between our findings and studies exploring
gene expression in ageing suggest that cell senescence
may play a role as a pathogenic mechanism of muscle
wasting in COPD. In fact, animal models of premature
ageing show structural changes in the lungs and skeletal
muscle that resemble those in COPD [90]. Shortening
of telomeres, a marker of premature ageing, has
been described in patients with COPD and muscle
wasting [21].Interestingly, as shown by Fredriksson et al. [83] in
septic patients admitted to an intensive care unit (ICU),
pro-inflammatory genes are up-regulated in the muscle
of these patients including several genes found in our
study. Moreover, they also found up-regulated genes re-
lated to cell cycle arrest including CDKN1A suggesting
that that cell senescence could be also a mechanism
leading to muscle wasting in this population. Moreover,
inflammation and oxidative stress, a feature of patients
with COPD and muscle wasting has been associated
with stress-induced premature senescence [91].
Interestingly, when exploring the effects of exercise in
skeletal muscle gene expression [86,87], while exercise
training contribute to “normalise” the expression of
genes related with energy production and oxidative cap-
acity of the muscle, several genes found up-regulated in
our COPD population were not modified (“normalized”)
by exercise training (including GADD45A, NNMT,
ANKRD1, ATF3 and SLC38A1) suggesting that the in-
creased expression of these genes in our population of
COPDL is not related to physical activity levels since this
should produce the opposite effect.
It is of note that the gene profile of patients with can-
cer [84] was not comparable to the profile of patients
with COPD and muscle wasting of our study proposing
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tions involve different underlying mechanisms.
Limitations of the study
We have used FFMI measured by bioimpedance as a sur-
rogate of muscle mass instead of a direct measurement of
muscle mass. One of the most validated definitions of sar-
copenia and severity of sarcopenia is based in BIA assess-
ment of muscle mass [92]. This method has been
validated against body composition assessed by deuterium
dilution [93] and dual-energy X-ray absorptiometry [94]
and shows very good correlation with other measure-
ments of limb muscle mass in patients with COPD [95].
FFMI measured by bioimpedance is an independent pre-
dictor of skeletal muscle function and exercise capacity
[96] and mortality [97] in patients with COPD. Moreover,
it is a very sensitive method to detect undernutrition in
these patients [98]. Values to differentiate muscle wasted
patients from patients with preserved muscle mass based
of FFMI have been established and validated in patients
with COPD [93]. In our population, FFMI related to
muscle function assessed as QMVC.
Physical activity (PA) can be seen as a confounding
variable in this study. It was assessed with two question-
naires instead of using a direct measurement (i.e. activity
monitors). PA assessed with the Voorrips questionnaire,
designed to be use in elderly populations, showed lower
physical activity levels in COPDL. It was difficult to re-
cruit patients with higher levels of PA assessed with this
tool. Interestingly, there was no difference in the level of
Activity of Daily Living assessed with the London Chest
Activity of Daily Living Scale. Moreover, key DEGs iden-
tified in the present study showed no modification in re-
sponse to exercise training in young [87] and elderly
[86] subjects making it less likely that these changes
were attributed to a lower PA level in this population.
Beside the efforts in matching the populations, healthy
control subjects present differences in average cessation
days and Pack/years in comparison to COPDL. Environ-
mental factors such as cigarette smoking may associate
with peripheral muscle alterations [99]. However, it is
unlikely to explain the differences in the transcriptome
in our population as all three groups were matched for
smoking status. Moreover, only one COPDL was an ac-
tive smoker, whilst the other two groups included two
active smokers each, which makes it less possible that
this is a conditioning factor for muscle wasting in this
group. Furthermore, no differences in the average cessa-
tion years, in cumulative history of smoking nor in age
at smoking cessation (which may have important impli-
cations on outcomes) [100] were seen between COPDL
and COPDN. Therefore, it is unlikely that the time post-
smoking cessation contributes to the differences in gene
expression between these groups.Conclusions
This study demonstrate that vastus lateralis of patients
with COPD and muscle wasting overexpress genes related
to inhibition of cell cycle and of cell growth while genes
related to muscle formation and growth and energy pro-
duction were down-regulated. This pattern is similar to
observations associated with ageing which, suggests that
premature ageing may play a role in muscle atrophy in
COPD. This profile, together with several genes involved
in inflammation signaling, were shared with the profile de-
scribed in severely ill patients in the ICU which suggest
both, that ICU patients may also experience cell senes-
cence in response to inflammation and that inflammation
may be a shared mechanism between COPD and ICU pa-
tients. These results may open new avenues for the treat-
ment of muscle wasting in patients with COPD. The most
challenging issue is to explore potential avenues for treat-
ment and identify the timing to treat these with anti-aging
agents considering that earlier diagnosis is a key for effect-
ive anti-aging therapy.
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